Noopept Research Overview (also known as Cognitive Enhancement Nootropic)
Omberacetam (also known as Noopept or GVS-111) is a synthetic nootropic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia in 1996 for its potent cognitive-enhancing and neuroprotective properties. While structurally distinct from racetams, it's considered part of the nootropic family and functions as a prodrug that converts to the active metabolite cycloprolylglycine (CPG). Research indicates it may enhance memory, learning, and neuroplasticity through BDNF/NGF upregulat
What Is Omberacetam (Noopept)?
Omberacetam (also known as Noopept or GVS-111) is a synthetic nootropic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) developed in Russia in 1996 for its potent cognitive-enhancing and neuroprotective properties. While structurally distinct from racetams, it's considered part of the nootropic family and functions as a prodrug that converts to the active metabolite cycloprolylglycine (CPG). Research indicates it may enhance memory, learning, and neuroplasticity through BDNF/NGF upregulation and glutamatergic modulation at doses 1000x lower than piracetam.
Mechanism of Action
Rapidly absorbed orally and converted to active metabolite cycloprolylglycine (CPG) which modulates AMPA/NMDA glutamate receptors and enhances cholinergic neurotransmission
Key Benefits
Primary administration route, rapid oral bioavailability, convenient dosing, well-studied in clinical trials, peak absorption within 7 minutes
Quick Reference
| Literature-Reported Dose Range | 10-20mg per administration |
| Literature-Reported Frequency | 1-3 times daily, morning and early afternoon preferred |
| Literature-Reported Cycle Length | 4-8 weeks continuous use recommended |
| Literature-Reported Washout | 2-4 weeks break between cycles to prevent tolerance |
| Storage | Room temperature, protect from moisture and light |
| Timing | Morning and early afternoon dosing optimal; avoid late evening due to potential alertness effects |
Research Indications
Cognitive
Memory Enhancement
Improved memory consolidation and retrieval through enhanced synaptic plasticity and neurotrophic factor expression
Learning Acceleration
Faster acquisition of new information via AMPA receptor modulation and enhanced long-term potentiation
Focus and Concentration
Sustained attention improvements through acetylcholine sensitization and glutamatergic enhancement
Neuroprotective
Oxidative Stress Protection
Antioxidant effects protecting neurons from free radical damage and lipid peroxidation
Anti-Inflammatory Action
Reduction of neuroinflammatory processes that contribute to cognitive decline
Excitotoxicity Prevention
Protection against excessive glutamate and calcium-mediated neuronal damage
Neuroplasticity
BDNF Upregulation
Rapid increase in brain-derived neurotrophic factor supporting neurogenesis and synaptic plasticity
NGF Enhancement
Elevated nerve growth factor expression promoting neuronal survival and differentiation
Synaptic Plasticity
Enhanced long-term potentiation and synaptic strength through glutamate receptor modulation
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Cognitive enhancement (beginner) | 10mg | 1-2 times daily | Oral (Sublingual or swallowed) |
| Standard cognitive support | 10-20mg | 2-3 times daily | Oral, taken with or without food |
| Intensive cognitive enhancement | 20-30mg | 2-3 times daily | Oral, cycled 4-8 weeks |
| Cognitive recovery support | 20mg | Twice daily | Oral (as studied in clinical trials) |
Timing
Morning and early afternoon dosing optimal; avoid late evening due to potential alertness effects. Typical onset: onset 20-60 minutes, peak 2 hours, duration 3-5 hours.
Peptide Interactions
Complementary cognitive enhancement through different mechanisms - Semax via ACTH pathways, Omberacetam via glutamatergic/cholinergic modulation
Selank provides anxiolytic effects that may complement Omberacetam's cognitive enhancement, potentially reducing nootropic-induced anxiety
Both compounds affect neurotransmitter systems - monitor for overstimulation when combining
Both support neuroplasticity through neurotrophic mechanisms; may have additive neuroprotective effects
Both are potent cognitive enhancers affecting growth factors - potential for excessive stimulation; start with lower doses if combining
Omberacetam increases acetylcholine sensitization; choline supplementation (Alpha-GPC, CDP-Choline) may prevent headaches and enhance effects
Reported Research Timeline
01Days 1–3 (reported in cited studies): subtle cognitive clarity and mild focus enhancement; possible initial headache if not using choline
02Week 1 (reported in cited studies): noticeable improvement in memory recall and verbal fluency; adjust dosing as needed
03Week 2–3 (reported in cited studies): enhanced learning capacity and sustained attention; mood stabilization effects may emerge
04Week 4–6 (reported in cited studies): peak cognitive benefits with improved stress resilience and mental stamina
05Week 6–8 (reported in cited studies): sustained effects; consider cycle break to maintain sensitivity
06Post-cycle: Gradual return to baseline over 1-2 weeks; some users report lasting improvements
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Start with 10mg once daily to assess individual response before increasing dose
Always pair with a choline source (Alpha-GPC or CDP-Choline) to prevent headaches
Avoid evening dosing as cognitive stimulation may interfere with sleep
Do not combine with other strong cholinergic or glutamatergic compounds without caution
Not recommended for pregnant or breastfeeding women due to lack of safety data
Individuals with liver conditions should consult healthcare provider before use
Seek Medical Attention If:
Persistent headaches that don't respond to choline supplementation
Unusual irritability, anxiety, or agitation
Sleep disturbances including insomnia or vivid dreams
Gastrointestinal discomfort that worsens with continued use
Increased blood pressure or heart palpitations
Any signs of allergic reaction (rash, swelling, difficulty breathing)
Quality Indicators
Verified Marker
White crystalline powder
Omberacetam should be white to off-white crystalline powder without discoloration
Verified Marker
Third-party testing
Certificate of analysis showing purity ≥98% with HPLC verification
Verified Marker
Proper packaging
Sealed containers protected from moisture with desiccant packets
Verified Marker
Accurate dosing
Tablets/capsules should contain stated amount (typically 10mg per unit)
Acceptable Range
Headache potential
May cause headaches if taken without adequate choline - supplement accordingly
Quality Concern
Discoloration or clumping
Yellow discoloration or excessive clumping may indicate degradation or contamination
Research Citations
- Neuroprotection in Alzheimer's Model (2015)
Cellular | Human cortical neurons | β-amyloid/tau phosphorylation model | Multiple concentrations - Neurotrophic Factor Expression (2009)
Animal | Rat | 0.5mg/kg IP | Single dose | Hippocampal analysis - Human Cognitive Enhancement Trial (2008)
Human | 53 patients | 20mg daily vs Piracetam 1200mg | 56 days | Cerebrovascular/post-traumatic conditions - Spatial Memory Restoration Study (2007)
Animal | Mouse Alzheimer's model | 0.01mg/kg daily | 21 days - [Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats]
Boyko SS, Zherdev VP, Shevchenko RV, 2018, Biomed Khim - Noopept normalizes parameters of the incretin system in rats with experimental diabetes
Ostrovskaya RU, Zolotov NN, Ozerova IV, 2014, Bull Exp Biol Med - Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Ostrovskaya RU, Vakhitova YV, Kuzmina USh, 2014, J Biomed Sci - The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model
Ostrovskaya RU, Gruden MA, Bobkova NA, 2007, J Psychopharmacol - Selective suppression of the slow-inactivating potassium currents by nootropics in molluscan neurons
Bukanova JV, Solntseva EI, Skrebitsky VG, 2002, Int J Neuropsychopharmacol
Research Focus
cognitive, neuroprotective, neuroplasticity
Verified Vendors Carrying Noopept
Frequently Asked Questions
What should researchers watch for with Noopept?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Noopept?
Days 1–3 (reported in cited studies): subtle cognitive clarity and mild focus enhancement; possible initial headache if not using choline
How is Noopept typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →